IMCR icon

Immunocore

30.40 USD
+0.00
0.00%
At close Jan 10, 4:00 PM EST
After hours
30.40
+0.00
0.00%
1 day
0.00%
5 days
0.53%
1 month
-4.55%
3 months
-1.59%
6 months
-20.06%
Year to date
1.95%
1 year
-58.19%
5 years
-29.63%
10 years
-29.63%
 

About: Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.

Employees: 497

0
Funds holding %
of 6,810 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

34% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 35

0.42% more ownership

Funds ownership: 90.05% [Q2] → 90.47% (+0.42%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

5% less capital invested

Capital invested by funds: $1.49B [Q2] → $1.41B (-$80.7M) [Q3]

7% less funds holding

Funds holding: 135 [Q2] → 126 (-9) [Q3]

27% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 26

56% less call options, than puts

Call options by funds: $6.62M | Put options by funds: $15M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$24
21%
downside
Avg. target
$54
76%
upside
High target
$100
229%
upside

5 analyst ratings

positive
40%
neutral
40%
negative
20%
Needham
Gil Blum
23% 1-year accuracy
38 / 165 met price target
134%upside
$71
Buy
Reiterated
10 Jan 2025
Morgan Stanley
Andrew Galler
0% 1-year accuracy
0 / 1 met price target
15%upside
$35
Equal-Weight
Downgraded
13 Dec 2024
Mizuho
Graig Suvannavejh
50% 1-year accuracy
15 / 30 met price target
25%upside
$38
Neutral
Downgraded
11 Nov 2024
UBS
David Dai
18% 1-year accuracy
2 / 11 met price target
21%downside
$24
Sell
Initiated
24 Oct 2024
HC Wainwright & Co.
Patrick Trucchio
34% 1-year accuracy
53 / 158 met price target
229%upside
$100
Buy
Reiterated
24 Oct 2024

Financial journalist opinion

Based on 9 articles about IMCR published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Positive
Zacks Investment Research
4 days ago
New Strong Buy Stocks for January 7th
AORT, VERX, NN, IMCR and EVER have been added to the Zacks Rank #1 (Strong Buy) List on January 7, 2024.
New Strong Buy Stocks for January 7th
Neutral
GlobeNewsWire
5 days ago
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
Neutral
GlobeNewsWire
1 week ago
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Positive
Zacks Investment Research
2 weeks ago
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
Positive
Zacks Investment Research
2 weeks ago
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
Neutral
GlobeNewsWire
2 weeks ago
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Positive
Zacks Investment Research
4 weeks ago
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy
Positive
Zacks Investment Research
4 weeks ago
New Strong Buy Stocks for December 12th
NBBK, OMCL, ZIM, IMCR and ULS have been added to the Zacks Rank #1 (Strong Buy) List on December 12, 2024.
New Strong Buy Stocks for December 12th
Neutral
GlobeNewsWire
1 month ago
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Charts implemented using Lightweight Charts™